Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Kamada-AAT for Inhalation in Alpha-1 Antitrypsin Deficiency
2024-516054-21-00Phase 3Completed
- Sponsor
- Kamada Ltd.
- Start
- Sep 2024
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 8
01
Overview
Phase 3, randomised, double-blind trial in alpha-1 antitrypsin deficiency (AATD) comparing Kamada-AAT for Inhalation arm with Placebo arm (2 arms). Primary endpoint: FEV1 (L) post bronchodilator change from baseline at 104 weeks. Started Sep 2024; status: completed.
02
Drugs
alpha1-proteinase inhibitor (human)
03
Conditions
alpha-1 antitrypsin deficiency (AATD)
Beyond the preview
Go deeper on 2024-516054-21-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-516054-21-00.